Credit Suisse 15/03/2010 1 Outperform $40.50 12.3%
Following news the company has received FDA approval for Hizentra the broker sees the subcutaneous immunoglobulin (SCIG) market the product is in as being worth as much as US$200m annually in sales.
It also notes the company has first mover advantage in the SCIG market, which should support margins in its view.
With the shares trading at a discount to their five-year average earnings multiple the broker retains its Outperform rating and $40.50 price target.
- Forums
- ASX - By Stock
- CSL
- credit suisse - $40.50
credit suisse - $40.50, page-24
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$309.60 |
Change
1.795(0.58%) |
Mkt cap ! $149.8B |
Open | High | Low | Value | Volume |
$310.21 | $311.38 | $309.45 | $42.94M | 138.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 38 | $309.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$309.65 | 58 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 63 | 309.880 |
2 | 16 | 309.860 |
4 | 66 | 309.850 |
1 | 23 | 309.840 |
3 | 33 | 309.830 |
Price($) | Vol. | No. |
---|---|---|
309.890 | 6 | 3 |
309.900 | 77 | 4 |
309.910 | 280 | 1 |
309.920 | 2 | 1 |
309.930 | 10 | 1 |
Last trade - 12.34pm 20/08/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |